Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma

Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent bendamustine as lymphodepleti...

Full description

Saved in:
Bibliographic Details
Main Authors: Crystal Mackall, Holden T Maecker, Lekha Mikkilineni, Melody Smith, Saurabh Dahiya, Bita Sahaf, David Miklos, Sally Arai, Surbhi Sidana, Wen-Kai Weng, Dasom Lee, Anmol Goyal, Sushma Bharadwaj, Eric Lau, Mark P Hamilton, Hrishi Srinagesh, Alexandria Jensen, Jayasindhu Mallampet, Sarah Elkordy, Shriya Syal, Sunita Patil, Theresa Latchford, Laura J Johnston, Robert Lowsky, Robert Negrin, Andrew R Rezvani, Judith Shizuru, Everett H Meyer, Parveen Shiraz, Lori Muffly, Matthew J Frank
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/7/e008975.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/7/e008975.full

Similar Items